Open AccessClinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
Author(s) -
Choi Hayoung,
Chang Jinsun,
Shin HongJoon,
Park CheolKyu,
Oh InJae,
Kim KyuSik,
Kim YoungChul
Publication year - 2015
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12171
Subject(s) - gefitinib , medicine , asymptomatic , adenocarcinoma , epidermal growth factor receptor , lung , oncology , tumor progression , exon , adenocarcinoma of the lung , lung cancer , gene , cancer , genetics , biology
We report a case showing the long‐term clinical benefit of the continued use of gefitinib in a patient with asymptomatic progression of lung adenocarcinoma harboring an exon 19 deletion of the epidermal growth factor receptor gene. Although follow‐up studies showed smoldering progression of metastatic lesions, continued treatment with gefitinib controlled pulmonary adenocarcinoma for more than six years.